quizartinib

FDA again delays Daiichi's plans to challenge Astellas and Novartis for blood cancer market
Fierce Biotech
Fri, 04/21/23 - 10:08 am
Daiichi Sankyo
Astellas
Novartis
quizartinib
FDA
blood cancer
FDA grants priority review for Daiichi Sankyo’s AML medicine
Pharmaceutical Business Review
Tue, 10/25/22 - 10:37 am
FDA
priority review
Daiichi Sankyo
quizartinib
acute myeloid leukemia
EHA: Survival data sets Daiichi Sankyo’s quizartinib back on track
Pharmaforum
Mon, 06/13/22 - 10:44 am
Daiichi Sankyo
EHA
quizartinib
clinical trials
acute myeloid leukemia
FDA declines to approve Daiichi Sankyo's blood cancer treatment
Reuters
Fri, 06/21/19 - 11:55 pm
Daiichi Sankyo
FDA
quizartinib
acute myeloid leukemia
Daiichi Sankyo Takes Two Products to FDA Advisory Panel; Gets One Yes, One No
BioSpace
Wed, 05/15/19 - 11:42 am
Daiichi Sankyo
FDA
quizartinib
acute myeloid leukemia
pexidartinib
TGCT
FDA questions credibility of Daiichi data ahead of AdComm
Fierce Biotech
Mon, 05/13/19 - 09:32 am
FDA
Daiichi Sankyo
quizartinib
acute myeloid leukemia
Daiichi Sankyo in pursuit of Novartis’ Rydapt with next-generation FLT3 drug
Fierce Biotech
Wed, 05/9/18 - 09:21 am
Novartis
Rydapt
acute myeloid leukemia
Daiichi Sankyo
quizartinib
Ambit's Oncology Drug in Phase III
Yahoo/Zacks.com
Wed, 04/9/14 - 09:34 pm
Ambit Biosciences
quizartinib
acute myeloid leukemia